Compare
Prestige Consumer Healthcare Inc. vs Acadia Pharmaceuticals Inc vs Indivior Pharmaceuticals, Inc. vs Harmony Biosciences Holdings, Inc.
| Latest fiscal year | Prestige Consumer Healthcare Inc. PBH | Acadia Pharmaceuticals Inc ACAD | Indivior Pharmaceuticals, Inc. INDV | Harmony Biosciences Holdings, Inc. HRMY |
|---|---|---|---|---|
| Year ended | 2026-03-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $1.09B | $1.07B | $1.24B | $868.45M |
| Revenue growth (YoY) | -4.3% | +11.9% | +4.3% | +21.5% |
| Gross margin | 54.7% | 91.7% (computed) | 80.2% | 77.2% |
| Operating margin | 28.4% | 9.8% | 21.1% | 24.0% |
| Net margin | 17.5% | 36.5% | 16.9% | 18.3% |
| Net income | $190.30M | $391.00M | $210.00M | $158.69M |
| EPS (Diluted) | $3.91 | $2.30 | $1.64 | $2.71 |
| Operating cash flow | $257.63M | $109.84M | -$27.00M | $348.20M |
| Free cash flow | $246.45M | $105.15M | -$93.00M | $347.89M |
| Cash & equivalents | $63.87M | $177.69M | $195.00M | $752.50M |
| Total assets | $3.49B | $1.56B | $1.20B | $1.27B |
| Total liabilities | $1.61B | $336.81M | $1.30B | $401.41M |
| Shareholders' equity | $1.89B | $1.23B | -$98.00M | $870.22M |
| Return on year-end equity | 10.1% | 31.9% | n/a | 18.2% |
| Shares outstanding | n/a | 170.31M | n/a | 57.73M |
Revenue, most recent five fiscal years
| Fiscal year | Prestige Consumer Healthcare Inc. | Acadia Pharmaceuticals Inc | Indivior Pharmaceuticals, Inc. | Harmony Biosciences Holdings, Inc. |
|---|---|---|---|---|
| Latest | $1.09B Ended 2026-03-31 | $1.07B Ended 2025-12-31 | $1.24B Ended 2025-12-31 | $868.45M Ended 2025-12-31 |
| 1 year earlier | $1.14B Ended 2025-03-31 | $957.80M Ended 2024-12-31 | $1.19B Ended 2024-12-31 | $714.73M Ended 2024-12-31 |
| 2 years earlier | $1.13B Ended 2024-03-31 | $726.44M Ended 2023-12-31 | $1.09B Ended 2023-12-31 | $582.02M Ended 2023-12-31 |
| 3 years earlier | $1.13B Ended 2023-03-31 | $517.24M Ended 2022-12-31 | $901.00M Ended 2022-12-31 | $437.86M Ended 2022-12-31 |
| 4 years earlier | $1.09B Ended 2022-03-31 | $484.14M Ended 2021-12-31 | n/a | $305.44M Ended 2021-12-31 |